Vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS)
Strain DV of PRRSV
Porcilis PRRS is a vaccine based on the European strain DV of PRRS virus. Intramuscular or intradermal injection of the attenuated live PRRSV strain DV results in active immunisation against infection with PRRS virus. This activity is enhanced by the adjuvant Diluvac Forte.
Each dose of 2 ml (intramuscular application) or 0.2 ml (intradermal application) contains at least 104 TCID50 of PRRS virus strain DV. The active component is dissolved in Diluvac Forte.
Live freeze-dried vaccine for reconstitution with the solvent Diluvac Forte.
For active immunisation of clinically healthy pigs in a PRRSV contaminated environment, to reduce viraemia caused by infection with European strains of PRRS virus.
For fattening pigs - the respiratory tropism is relevant. A significant improvement of rearing results (reduced morbidity due to PRRS infection, and a better daily growth and feed conversion) until the end of the fattening period was observed in vaccinated pigs during field trials.
For breeding pigs - the reproductive tropism is relevant. A significant improvement of the reproductive performance in PRRSV contaminated environments and a reduction of transplacental virus transmission after challenge was observed in vaccinated pigs .
The interest of vaccination with Porcilis PRRS lies in obtaining a homogeneous and high immune status against PRRSV in a herd.
A single dose is given to pigs from 2 weeks of age onwards. Pigs should be vaccinated at least 2-4 weeks before a PRRSV infection occurs. It is advised to vaccinate all target pigs within a herd from the earliest recommended age onward. A single vaccination is sufficient for protection until slaughter.
For gilts a (re)vaccination 2-4 weeks before mating is recommended. To maintain a high homologous level of immunity, revaccination at regular intervals is recommended, either before each consecutive gestation or at random at 4 month intervals.
Pregnant sows should only be vaccinated after previous exposure to European PRRSV.
Newly introduced PRRSV-nave animals (e.g. replacement gilts from PRRSv-negative herds) should be vaccinated prior to pregnancy.
2 ml by the intramuscular route or 0.2 ml by the intradermal route. See Intradermal application.
A small, transient, intradermal lump observed after the intradermal application is indicative of the appropriate vaccination technique.
Vials of freeze-dried vaccine containing 10, 25, 50 or 100 doses.
Store at a temperature of 2-8C. Protect from light. The adjuvant Diluvac Forte should be stored at 25C.
Do not use the vaccine in herds where the prevalence of European PRRSV has not been established through reliable diagnostic methods.